What is the Alzheimer’s Tau Platform (ATP) Study?

This is a 30-month double-blind, randomized, Phase II platform trial designed to accelerate testing of promising investigational therapies that target tau, a key driver of Alzheimer’s disease.

What is the purpose of the Alzheimer’s Tau Platform (ATP) Study?

The purpose of the ATP Study is to evaluate whether investigational treatments targeting tau, alone or with an amyloid-lowering treatment, can slow early changes associated with Alzheimer’s disease.

Eligibility

The participants in this study must be between the ages of 50-80 with either no symptoms or mild symptoms of Alzheimer’s disease. Participants must have a study partner, who has at least weekly contact with them, who can accompany them to some study visits. Participants should be willing to complete all study procedures such a blood test and brain imaging.

Interested participants can contact the Memory and Aging Program Outreach Team at (401) 455-6402 or by sending an email to memory@butler.org to discuss additional eligibility criteria.